Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 10, 2008, Pages 601-609

  Lian, Tzi Wei ^a   Wang, Lisu ^b,c   Lo, Ya Hsuan ^a   Huang, I Jen ^d   Wu, Ming Jiuan ^a  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b Chia Nan Psychiatric Center   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Taiwan Sugar Research Institute   (Taiwan)

Author keywords

Atherogenesis; CD36; Fisetin; Morin; Myricetin; PPAR ; U937 cells

Indexed keywords

ALKADIENE; CD36 ANTIGEN; CELL SURFACE PROTEIN; COPPER; FISETIN; FLAVONOL DERIVATIVE; MALONALDEHYDE; MESSENGER RNA; MORIN; MYRICETIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PERCHLORATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCAVENGER RECEPTOR; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AEROBIC METABOLISM; ANTIGEN EXPRESSION; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATTENUATION; CELL STRAIN U937; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ELECTROPHORETIC MOBILITY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID PEROXIDATION; LIPID TRANSPORT; MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANILIDES; ANTIGENS, CD36; ANTIOXIDANTS; BLOTTING, WESTERN; COPPER; ENDOCYTOSIS; FLAVONOIDS; FLAVONOLS; GENE EXPRESSION; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MOLECULAR STRUCTURE; PPAR GAMMA; PROSTAGLANDIN D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCAVENGER RECEPTORS, CLASS A; STATIC ELECTRICITY; TETRADECANOYLPHORBOL ACETATE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; U937 CELLS;

EID: 52049097043     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.06.009     Document Type: Article

References (61)

1. Munteanu A., Taddei M., Tamburini I., Bergamini E., Azzi A., and Zingg J.-M. Antagonistic effects of oxLDL and alpha-tocopherol on CD36 scavenger receptor expression in monocytes; involvement of PKB and PPARgamma. J. Biol. Chem. 281 (2006) 6489-6497
2. Yamada Y., Doi T., Hamakubo T., and Kodama T. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol. Life Sci. 54 (1998) 628-640
3. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268 (1993) 11811-11816
4. Nakata A., Nakagawa Y., Nishida M., Nozaki S., Miyagawa J., Nakagawa T., Tamura R., Matsumoto K., Kameda-Takemura K., Yamashita S., and Matsuzawa Y. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1333-1339
5. Hajjar D.P., and Haberland M.E. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J. Biol. Chem. 272 (1997) 22975-22978
6. Han J., Hajjar D.P., Febbraio M., and Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J. Biol. Chem. 272 (1997) 21654-21659
7. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., and Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105 (2000) 1049-1056
8. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Kodama T., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386 (1997) 292-296
9. Babaev V.R., Gleaves L.A., Carter K.J., Suzuki H., Kodama T., Fazio S., and Linton M.F. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2593-2599
10. Sakaguchi H., Takeya M., Suzuki H., Hakamata H., Kodama T., Horiuchi S., Gordon S., van der Laan L.J., Kraal G., Ishibashi S., Kitamura N., and Takahashi K. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab. Invest. 78 (1998) 423-434
11. Herijgers N., de Winther M.P., Van Eck M., Havekes L.M., Hofker M.H., Hoogerbrugge P.M., and Van Berkel T.J. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J. Lipid Res. 41 (2000) 1402-1409
12. Kuchibhotla S., Vanegas D., Kennedy D.J., Guy E., Nimako G., Morton R.E., and Febbraio M. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc. Res. 78 (2008) 185-196
13. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
14. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
15. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., and Mann G.E. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 94 (2004) 609-616
16. Tontonoz P., Hu E., and Spiegelman B.M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev. 5 (1995) 571-576
17. Schoonjans K., Martin G., Staels B., and Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8 (1997) 159-166
18. Aviram M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxid. Redox Signal. 1 (1999) 585-594
19. Fuhrman B., Volkova N., Coleman R., and Aviram M. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J. Nutr. 135 (2005) 722-728
20. Fuhrman B., and Aviram M. Anti-atherogenicity of nutritional antioxidants. IDrugs 4 (2001) 82-92
21. Fuhrman B., and Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr. Opin. Lipidol. 12 (2001) 41-48
22. Munteanu A., Zingg J.M., Ricciarelli R., and Azzi A. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol. Free Radic. Biol. Med. 38 (2005) 1047-1056
23. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet 24 (1976) 117-191
24. Kandaswami C., Middleton, and Jr. E. Free radical scavenging and antioxidant activity of plant flavonoids. Adv. Exp. Med. Biol. 366 (1994) 351-376
25. Ferrali M., Signorini C., Caciotti B., Sugherini L., Ciccoli L., Giachetti D., and Comporti M. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett. 416 (1997) 123-129
26. Wang L., Tu Y.C., Lian T.W., Hung J.T., Yen J.H., and Wu M.J. Distinctive antioxidant and antiinflammatory effects of flavonols. J. Agric. Food Chem. 54 (2006) 9798-9804
27. Arai Y., Watanabe S., Kimira M., Shimoi K., Mochizuki R., and Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr. 130 (2000) 2243-2250
28. German J.B., and Walzem R.L. The health benefits of wine. Annu. Rev. Nutr. 20 (2000) 561-593
29. Hakkinen S.H., Karenlampi S.O., Heinonen I.M., Mykkanen H.M., and Torronen A.R. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem. 47 (1999) 2274-2279
30. Knekt P., Kumpulainen J., Jarvinen R., Rissanen H., Heliovaara M., Reunanen A., Hakulinen T., and Aromaa A. Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76 (2002) 560-568
31. Hertog M.G., Hollman P.C., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 20 (1993) 21-29
32. Gotto, Jr. A.M., Pownall H.J., and Havel R.J. Introduction to the plasma lipoproteins. Methods Enzymol. 128 (1986) 3-41
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
34. Hermann M., and Gmeiner B. Altered susceptibility to in vitro oxidation of LDL in LDL complexes and LDL aggregates. Ann. N Y Acad. Sci. 683 (1993) 363-364
35. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6 (1989) 67-75
36. Hirakata M., Tozawa R., Imura Y., and Sugiyama Y. Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem. Biophys. Res. Commun. 323 (2004) 782-788
37. Steinbrecher U.P., Zhang H.F., and Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic. Biol. Med. 9 (1990) 155-168
38. Steinbrecher U.P., Witztum J.L., Parthasarathy S., and Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 7 (1987) 135-143
39. Kleinveld H.A., Hak-Lemmers H.L., Stalenhoef A.F., and Demacker P.N. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin. Chem. 38 (1992) 2066-2072
40. Luan Y., and Griffiths H.R. Ceramides reduce CD36 cell surface expression and oxidised LDL uptake by monocytes and macrophages. Arch. Biochem. Biophys. 450 (2006) 89-99
41. Han S., and Sidell N. Peroxisome-proliferator-activated-receptor gamma (PPARgamma) independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology 106 (2002) 53-59
42. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114 (2004) 1564-1576
43. de Whalley C.V., Rankin S.M., Hoult J.R., Jessup W., and Leake D.S. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. 39 (1990) 1743-1750
44. Safari M.R., and Sheikh N. Effects of flavonoids on the susceptibility of low-density lipoprotein to oxidative modification. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 73-77
45. Naderi G.A., Asgary S., Sarraf-Zadegan N., and Shirvany H. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol. Cell Biochem. 246 (2003) 193-196
46. Miura S., Watanabe J., Sano M., Tomita T., Osawa T., Hara Y., and Tomita I. Effects of various natural antioxidants on the Cu(2+)-mediated oxidative modification of low density lipoprotein. Biol. Pharm. Bull. 18 (1995) 1-4
47. Lotito S.B., and Frei B. Dietary flavonoids attenuate tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells. Structure-function relationships and activity after first pass metabolism. J. Biol. Chem. 281 (2006) 37102-37110
48. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138 (1999) S419-420
49. Yesner L.M., Huh H.Y., Pearce S.F., and Silverstein R.L. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1019-1025
50. Feng J., Han J., Pearce S.F.A., Silverstein R.L., Gotto, Jr. A.M., Hajjar D.P., and Nicholson A.C. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-{gamma}. J. Lipid Res. 41 (2000) 688-696
51. Huh H.Y., Pearce S.F., Yesner L.M., Schindler J.L., and Silverstein R.L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87 (1996) 2020-2028
52. Jiang C., Ting A.T., and Seed B. PPAR-[gamma] agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
53. Feng J., Han J., Pearce S.F., Silverstein R.L., Gotto, Jr. A.M., Hajjar D.P., and Nicholson A.C. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J. Lipid Res. 41 (2000) 688-696
54. Perez A., Thuillard J.L., Bentzen C.L., and Niesor E.J. Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell Biol. Toxicol. 19 (2003) 95-105
55. von Knethen A., Soller M., Tzieply N., Weigert A., Johann A.M., Jennewein C., Kohl R., and Brune B. PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J. Cell Biol. 176 (2007) 681-694
56. Devaraj S., Hugou I., and Jialal I. Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages. J. Lipid Res. 42 (2001) 521-527
57. Kroon P.A., Clifford M.N., Crozier A., Day A.J., Donovan J.L., Manach C., and Williamson G. How should we assess the effects of exposure to dietary polyphenols in vitro?. Am. J. Clin. Nutr. 80 (2004) 15-21
58. Spencer J.P., Abd-el-Mohsen M.M., and Rice-Evans C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch. Biochem. Biophys. 423 (2004) 148-161
59. Spencer J.P., Kuhnle G.G., Williams R.J., and Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem. J. 372 (2003) 173-181
60. Manach C., Williamson G., Morand C., Scalbert A., and Remesy C. Bioavailability and bioefficacy of polyphenols in humans: I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81 (2005) 230S-242S
61. Williamson G., and Manach C. Bioavailability and bioefficacy of polyphenols in humans: II. Review of 93 intervention studies. Am. J. Clin. Nutr. 81 (2005) 243S-255S